FindTrial
Sign In

Modified FOLFOX6

DRUG9 trials

Sponsors

Amgen, European Organisation for Research and Treatment of Cancer - EORTC, Seoul National University Hospital, Georgetown University, Five Prime Therapeutics, Inc.

Conditions

Advanced Gastric CancerAdvanced Solid TumorsCarcinoidColon CancerColorectal CancerColorectal Cancer MetastaticEsophageal CancerGastric Cancer

Phase 1

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
CompletedNCT00625651
AmgenColon Cancer, Colorectal Cancer, Metastatic Colorectal Cancer +1
Start: 2007-10-31End: 2011-09-30Updated: 2014-04-25
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
CompletedNCT03343301
Five Prime Therapeutics, Inc.Gastric Cancer, Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic
Start: 2017-11-30End: 2019-01-31Updated: 2024-02-28
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
CompletedNCT03798626
Novartis PharmaceuticalsColorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
Start: 2019-05-22End: 2025-02-05Updated: 2026-04-01

Phase 2

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
CompletedNCT01327612
AmgenAdvanced Solid Tumors, Carcinoid, Colorectal Cancer +6
Start: 2011-03-03End: 2020-02-05Updated: 2021-02-21
Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
WithdrawnNCT01646554
European Organisation for Research and Treatment of Cancer - EORTCColorectal Cancer Metastatic, KRAS Mutated Colorectal Cancer, Liver Metastases
Start: 2012-12-31End: 2016-12-31Updated: 2017-05-09
Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer
CompletedNCT02142322
Seoul National University HospitalAdvanced Gastric Cancer
Start: 2004-06-30End: 2011-06-30Updated: 2025-04-17
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
CompletedNCT03694522
Five Prime Therapeutics, Inc.Gastric Cancer
Start: 2018-09-14End: 2022-05-13Updated: 2024-02-28
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
TerminatedNCT04952753
Novartis PharmaceuticalsMetastatic Colorectal Cancer
Start: 2021-11-15End: 2025-01-20Updated: 2025-03-26

Unknown Phase

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
TerminatedNCT02358863
Georgetown UniversityEsophageal Cancer, Gastric Cancer
Start: 2015-02-28End: 2016-11-30Updated: 2018-09-06

Related Papers

Phase Ib study of gevokizumab (GEVO) in combination with standard-of-care (SoC) anticancer therapies in patients (pts) with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC), and metastatic renal cell cancer (mRCC).
Journal of Clinical Oncology2025-01-27
Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial
JCO Precision Oncology2025-01-2413 citations
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
Frontiers in Oncology2024-10-298 citations
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis
Gastric Cancer2024-06-119 citations
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
2024-02-0340 citations
New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology2023-01-24
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
2022-10-14162 citations
Abstract 2187: Circulating tumor DNA (ctDNA) gene sequencing results from prospective screening of patients with newly diagnosed metastatic gastric and gastroesophageal adenocarcinoma (GEA) for the bemarituzumab FIGHT randomized trial using a plasma NGS assay
Cancer Research2021-07-01
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).
Journal of Clinical Oncology2021-05-2036 citations
Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
Journal of Clinical Oncology2021-01-2076 citations
Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial
Cancer Chemotherapy and Pharmacology2020-09-236 citations
Antibodies to watch in 2020.
2020-01-01328 citations
Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design
Future Oncology2019-05-1667 citations
Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).
Journal of Clinical Oncology2019-01-2911 citations
FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.
Journal of Clinical Oncology2018-05-204 citations